Reminder of ImmunityBio Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy IBRX?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, resulting in investor losses when the truth emerged, highlighting significant transparency and compliance issues within the company.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases, urging investors to choose their legal counsel wisely.
- Participation Method: Investors can obtain more information by visiting Rosen Law Firm's website or calling toll-free at 866-767-3653, emphasizing that until the class is certified, investors may choose to retain or change their legal counsel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.140
Low
5.00
Averages
7.33
High
9.00
Current: 7.140
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, resulting in investor losses when the truth emerged, highlighting significant transparency and compliance issues within the company.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases, urging investors to choose their legal counsel wisely.
- Participation Method: Investors can obtain more information by visiting Rosen Law Firm's website or calling toll-free at 866-767-3653, emphasizing that until the class is certified, investors may choose to retain or change their legal counsel.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Investigation Initiated: Faruqi & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased or acquired securities between January 19, 2026, and March 24, 2026, aiming to provide legal support for affected investors.
- Investor Rights Reminder: The firm reminds investors that May 26, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their legal rights.
- Direct Contact Channels: Investors who have suffered losses can directly call Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options and ensure they receive professional guidance.
- Securities Litigation Context: This investigation highlights the legal risks ImmunityBio may face, prompting investors to stay informed about developments to take timely measures against potential financial losses.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that purchasers of ImmunityBio securities from January 19 to March 24, 2026, can seek lead plaintiff status, highlighting investor concerns over potential legal risks facing the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its Executive Chairman made false or misleading statements during the Class Period, claiming that their lead product Anktiva could make all NMIBC patients cancer-free long-term without supporting evidence, potentially undermining investor confidence.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio's CEO, indicating that misleading advertising for Anktiva led to a 21% drop in stock price following the news, reflecting market concerns regarding the company's compliance and credibility.
- Law Firm Strength: Robbins Geller ranked #1 in securities class action recoveries in 2025, recovering over $916 million for investors, showcasing its strong capabilities in securities fraud and shareholder rights litigation, which may encourage more investors to join the lawsuit seeking compensation.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions from improper marketing practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials falsely claimed Anktiva could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to come forward, indicating that the company's legal risks could adversely affect future financing and market trust.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading claims not only jeopardize investor interests but also pose serious public health risks by creating false expectations about Anktiva's treatment capabilities, potentially misleading patients regarding their treatment options.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Computer Lawsuit: Super Micro Computer (NASDAQ:SMCI) faces a class action lawsuit for failing to disclose that sales to Chinese companies violated U.S. export control laws, with investor losses exceeding $50,000 and a lead plaintiff deadline of May 26, 2026, potentially damaging the company's reputation and stock price.
- ImmunityBio Issues: ImmunityBio (NASDAQ:IBRX) is being sued for overstating Anktiva's capabilities, with investor losses during the class period potentially affecting future financing, and the lead plaintiff deadline is also May 26, 2026.
- Pinterest Revenue Decline: Pinterest (NYSE:PINS) faces a class action lawsuit for not disclosing risks of declining advertising revenues, with investor losses before February 12, 2026, possibly leading to company restructuring, and the lead plaintiff deadline is May 29, 2026.
- New Era Energy Fraud Allegations: New Era Energy (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent schemes, with investor losses potentially impacting financial transparency, and the lead plaintiff deadline is June 1, 2026.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation for their losses, demonstrating a commitment to safeguarding investor rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, underscoring the importance of participating in the lawsuit to protect their interests.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, resulting in investor losses when the truth emerged, highlighting significant transparency and compliance issues within the company.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases, urging investors to choose their legal counsel wisely.
- Participation Method: Investors can obtain more information by visiting Rosen Law Firm's website or calling toll-free at 866-767-3653, emphasizing that until the class is certified, investors may choose to retain or change their legal counsel.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Investigation Initiated: Faruqi & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased or acquired securities between January 19, 2026, and March 24, 2026, aiming to provide legal support for affected investors.
- Investor Rights Reminder: The firm reminds investors that May 26, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their legal rights.
- Direct Contact Channels: Investors who have suffered losses can directly call Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options and ensure they receive professional guidance.
- Securities Litigation Context: This investigation highlights the legal risks ImmunityBio may face, prompting investors to stay informed about developments to take timely measures against potential financial losses.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that purchasers of ImmunityBio securities from January 19 to March 24, 2026, can seek lead plaintiff status, highlighting investor concerns over potential legal risks facing the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its Executive Chairman made false or misleading statements during the Class Period, claiming that their lead product Anktiva could make all NMIBC patients cancer-free long-term without supporting evidence, potentially undermining investor confidence.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio's CEO, indicating that misleading advertising for Anktiva led to a 21% drop in stock price following the news, reflecting market concerns regarding the company's compliance and credibility.
- Law Firm Strength: Robbins Geller ranked #1 in securities class action recoveries in 2025, recovering over $916 million for investors, showcasing its strong capabilities in securities fraud and shareholder rights litigation, which may encourage more investors to join the lawsuit seeking compensation.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions from improper marketing practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials falsely claimed Anktiva could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to come forward, indicating that the company's legal risks could adversely affect future financing and market trust.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading claims not only jeopardize investor interests but also pose serious public health risks by creating false expectations about Anktiva's treatment capabilities, potentially misleading patients regarding their treatment options.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Computer Lawsuit: Super Micro Computer (NASDAQ:SMCI) faces a class action lawsuit for failing to disclose that sales to Chinese companies violated U.S. export control laws, with investor losses exceeding $50,000 and a lead plaintiff deadline of May 26, 2026, potentially damaging the company's reputation and stock price.
- ImmunityBio Issues: ImmunityBio (NASDAQ:IBRX) is being sued for overstating Anktiva's capabilities, with investor losses during the class period potentially affecting future financing, and the lead plaintiff deadline is also May 26, 2026.
- Pinterest Revenue Decline: Pinterest (NYSE:PINS) faces a class action lawsuit for not disclosing risks of declining advertising revenues, with investor losses before February 12, 2026, possibly leading to company restructuring, and the lead plaintiff deadline is May 29, 2026.
- New Era Energy Fraud Allegations: New Era Energy (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent schemes, with investor losses potentially impacting financial transparency, and the lead plaintiff deadline is June 1, 2026.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation for their losses, demonstrating a commitment to safeguarding investor rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, underscoring the importance of participating in the lawsuit to protect their interests.
See More
